Zeeuw, D. d, Akizawa, T., Agarwal, R., Audhya, P., Bakris, G. L, Chin, M. P, Krauth, M., Lambers Heerspink, H. J, Meyer, C. J, McMurray, J. J, Parving, H., Pergola, P. E, Remuzzi, G., Toto, R. D, Vaziri, N. D, Wanner, C., Warnock, D. G, Wittes, J. T & Chertow, GM. (2013). Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (BEACON). American Journal of Nephrology,37(3), 212-222. Switzerland: S. Karger AG. Retrieved from https://doi.org/10.1159/000346948
Chronic kidney disease ( CKD ) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of the renin-angiotensin-aldosterone system ( RAAS ). Bardoxolone methyl, a synthetic triterpenoid that reduces oxidative stress and inflammation through Nrf2 activation and inhibition of NF-κB was previously shown to increase estimated glomerular filtration rate ( eGFR ) in patients with CKD associated with type 2 diabetes mellitus. To date, no antioxidant or anti-inflammatory therapy has proved successful at slowing the progression of CKD.
Mary MacKillop Institute for Health Research
Access may be restricted.